RecruitingNot ApplicableNCT06950437

pBFS Guided aiTBS Over Language Network for ASD Child

Transcranial Magnetic Stimulation Guided by Personalized Brain Functional Sectors (pBFS) for Language Deficit Comorbid in Autism Spectrum Disorder Child: a Multi-center, Randomized, Sham-controlled Trial


Sponsor

Beijing Changping Tianhe Research Institute of Brain Science

Enrollment

150 participants

Start Date

Apr 25, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The aim of this trial is to evaluate the efficacy and safety of precision neuromodulation in improving language ability in children with autism spectrum disorder (ASD) who also have language development delay. The neuromodulation will be delivered using the accelerated intermittent theta burst stimulation (aiTBS) protocol, targeting the language network in the left superior frontal gyrus (SFG), guided by personalized Brain Functional Sector (pBFS) technology.


Eligibility

Min Age: 3 YearsMax Age: 6 Years

Inclusion Criteria8

  • Professionally diagnosed with ASD per DSM - 5 criteria.
  • Aged 3 - 6.5 years, either gender.
  • ADOS-2 results meet ASD standard cut - off.
  • SCQ score: ≥15 (age ≥ 4 years) or ≥11 (age \< 4 years).
  • Co-existing language disorder not explaining ASD symptoms. No organic speech organ lesions. CNBS-R2016 and CLAS-TP language-related equivalent age \> 18 months; any CLAS-TP dimension score \< 6.
  • Mandarin is the daily communication language.
  • May have intellectual/global developmental delay not explaining ASD symptoms.
  • Guardians volunteer, can cooperate in treatment and sign informed consent.

Exclusion Criteria11

  • Identified genetic pathogenic factors; current/past comorbid severe disorders (ADHD, Tourette's, etc.).
  • Serious self-harm in the past year.
  • Severe sensory/motor disorders precluding cooperation.
  • History of epileptic seizures.
  • Serious organic diseases, especially brain related.
  • Contraindications for MRI/TMS (metal/implants).
  • Respiratory/circulatory diseases with sedation risk.
  • Illiterate guardians unable to handle informed consent/questionnaires.
  • Received neuromodulation in the past 3 months.
  • Currently in other clinical trials.
  • Deemed unfit by the researcher.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEactive iTBS

Participants will undergo three iTBS sessions per day, with 1800 pulses per session, over a 12-week period. Individualized targets will be generated using the pBFS technique.

DEVICESham iTBS

Participants will undergo three sham iTBS sessions per day, with 1800 pulses per session, over a 12-week period. Sham stimulation will be delivered through a sham coil with the identical appearance as real coil. Individualized targets will be generated using the pBFS technique.

BEHAVIORALspeech therapy

Speech therapy will be delivered between iTBS/sham sessions. Two 30-minutes trainings every day.


Locations(1)

Peking University Sixth Hospital

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06950437


Related Trials